A panelist discusses how targeted gene therapy, particularly nadofaragene firadenovec, represents a paradigm shift in BCG-unresponsive NMIBC treatment.
Video Player is loading.
Play Video
Play
Mute
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -0:00
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off, selected
Captions
captions settings, opens captions settings dialog
captions off, selected
Audio Track
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Reset restore all settings to the default valuesDone
Close Modal Dialog
End of dialog window.
Close Modal Dialog
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC?
What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, and how does nadofaragene firadenovec fit into this landscape overall?